Natural toxins implicated in the development of Parkinson’s disease
- 2 September 2011
- journal article
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 4 (6), 361-373
- https://doi.org/10.1177/1756285611413004
Abstract
Experimental models of Parkinson’s disease (PD) are of great importance for improving the design of future clinical trials. Various neurotoxic models are available, including 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat and rotenone. However, no model is considered perfect; each has its own limitations. Based on epidemiological data, a new trend of using environmental toxins in PD modeling seems attractive and has dominated public discussions of the disease etiology. A search for new environmental toxin-based models would improve our knowledge of the pathology of the condition. Here, we discuss some toxins of natural origin (e.g. cycad-derived toxins, epoxomicin, Nocardia asteroides bacteria, Streptomyces venezuelae bacteria, annonacin and DOPAL) that possibly represent a contributory environmental component to PD.This publication has 77 references indexed in Scilit:
- Genetic Analysis of Pathways to Parkinson DiseaseNeuron, 2010
- Genetic Animal Models of Parkinson's DiseaseNeuron, 2010
- Transfer of a cyanobacterial neurotoxin within a temperate aquatic ecosystem suggests pathways for human exposureProceedings of the National Academy of Sciences of the United States of America, 2010
- Environmental neurotoxin‐induced progressive model of parkinsonism in ratsAnnals of Neurology, 2010
- Modeling PD pathogenesis in mice: Advantages of a chronic MPTP protocolParkinsonism & Related Disorders, 2008
- Neurodegenerative Diseases: Neurotoxins as Sufficient Etiologic Agents?NeuroMolecular Medicine, 2007
- Nocardia asteroides strain GUH-2 induces proteasome inhibition and apoptotic death of cultured cellsResearch in Microbiology, 2007
- Proteasome inhibition and Parkinson's disease modelingAnnals of Neurology, 2006
- Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeysAnnals of Neurology, 2006
- Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's diseaseAnnals of Neurology, 2004